Full Logo - OKYO .jpg
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
23. Oktober 2024 07:00 ET | OKYO Pharma LTD
OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled,...
Full Logo - OKYO .jpg
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
16. Oktober 2024 07:00 ET | OKYO Pharma LTD
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The...
Full Logo - OKYO .jpg
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
09. Oktober 2023 07:00 ET | OKYO Pharma LTD
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with...
Full Logo - OKYO .jpg
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         
28. Juli 2023 07:01 ET | OKYO Pharma LTD
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members
17. Februar 2022 17:42 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
TuftsCSDD-Logo-Color.jpg
Protocol Design Optimization Is Starting to Improve Clinical Study Performance, According to the Tufts Center for the Study of Drug Development
09. September 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...
TuftsCSDD-Logo-Color.jpg
Drug Company Collaborations to Reduce Development Risk Are Increasing, According to Tufts Center for the Study of Drug Development
07. August 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...
TuftsCSDD-Logo-Color.jpg
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
10. Juli 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...
TuftsCSDD-Logo-Color.jpg
Risk-Sharing Drug Development Programs Experience Longer Development Times, According to the Tufts Center for the Study of Drug Development
08. Mai 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...
TuftsCSDD-Logo-Color.jpg
Drug Developers Circumspect About Using Social Media in Clinical Research, According to the Tufts Center for the Study of Drug Development
06. März 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 6, 2014) - Social media is gaining ground as an important tool to improve the clinical research process through more effective engagement of patient communities, but...